From Startup Brainstorm Cell Therapeutics
Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2372061
Conference Call and Live Webcast at 8:30am Eastern Time
NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the third quarter ended September 30, 2018, and provide a corporate update, on Monday, October 29 at 8:30am Eastern Time.
Monday, October 29, 2018 @ 8:30am Eastern Time
1809 212 909
Replays, available through November 12, 2018
About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company has developed the NurOwn® technology into a commercially viable product. NurOwn® has been already administered to over 70 patients with ALS in clinical trials conducted in the United States and in Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. The Company is currently conducting a Phase 3 double blind, placebo-controlled clinical trial at multiple clinical sites throughout the US. For more information, visit the company’s website at www.brainstorm-cell.com.
CONTACTSMedia:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: (646) email@example.com
Investors:Michael RiceLifeSci Advisors, LLCPhone: firstname.lastname@example.org
BrainStorm Cell Therapeutics Inc.
Please visit their site for more information: Brainstorm Cell Therapeutics.com
All,Biotechnology,Healthcare News,Startup News